分组1 - Bioventus reported quarterly earnings of $0.06 per share, matching the Zacks Consensus Estimate, and an increase from $0.05 per share a year ago [1] - The company achieved revenues of $138.96 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 4.82%, and up from $120.79 million year-over-year [2] - Bioventus shares have increased approximately 160.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 19.8% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $147.53 million, and for the current fiscal year, it is $0.40 on revenues of $560.78 million [7] - The Medical - Drugs industry, to which Bioventus belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Exhibit 99.1 Bioventus Reports Third Quarter Financial Results • Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* Growth • Q3 Gross Margin Expanded 200 bps • Q3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared to Previous Year DURHAM, NC – November 5, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, ...

Core Insights - Bioventus Inc. reported a 15.0% increase in Q3 revenue, marking the fourth consecutive quarter of double-digit organic growth, driven by strong performance in Pain Treatments and Surgical Solutions [2][5] - The company achieved a gross margin expansion of 200 basis points and generated cash from operations of $10.3 million, an increase of $18.6 million compared to the previous year [1][3] - The net loss from continuing operations decreased to $5.4 million from $8.8 million in the prior-year period, with adjusted EBITDA rising 8.4% to $23.6 million [3][4] Financial Performance - Q3 2024 worldwide revenue reached $139.0 million, up from $120.8 million in Q3 2023, with notable growth in Pain Treatments (16.3%) and Surgical Solutions (18.6%) [2][5] - Adjusted EBITDA for the third quarter was $23.6 million, reflecting strong revenue growth compared to $21.7 million in the prior year [3][35] - The company reported a loss per share of $0.07, an improvement from a loss of $0.12 in the prior-year period [4][18] Revenue Breakdown - U.S. net sales totaled $122.9 million, a 15.7% increase year-over-year, with Pain Treatments contributing $56.3 million and Surgical Solutions $41.2 million [5][6] - International net sales amounted to $16.1 million, a 10.2% increase, with Pain Treatments growing by 29.3% [5][6] Strategic Developments - Bioventus is focused on executing strategic priorities to enhance revenue growth and profitability while reducing leverage to increase shareholder value [2][7] - The company has reached an agreement to divest its Advanced Rehabilitation Business for up to $45.0 million, expected to close by early 2025, which will help reduce debt and concentrate on core businesses [7][8] Future Guidance - For the twelve months ending December 31, 2024, Bioventus expects net sales between $562 million and $567 million, with adjusted EBITDA projected at $104 million to $107 million [8]

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Bioventus (BVS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Bioventus is one of 1024 companies in the Medical group. The Medical group currently sits ...

Bioventus (BVS) is expected to report third-quarter 2024 earnings next month. The Zacks Consensus Estimate for sales and earnings is pegged at $132.6 million and 6 cents per share, respectively.Estimates for Bioventus’ 2024 and 2025 earnings per share (EPS) have remained consistent in the past 60 days at 40 and 45 cents, respectively. The company delivered an earnings surprise of 171.43% in the last reported quarter. Image Source: Zacks Investment ResearchBVS’ Earnings Surprise HistoryThe company’s earnings ...

DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0 ...

Shares of Bioventus (BVS) have surged 73% in the past three months, significantly outperforming the industry’s 1.3% growth. The stock has outperformed the sector and the S&P 500 during the same period. BVS' shares are also trading above the 50-day and 200-day moving averages.BVS Stock Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchThis uptick in stock price was triggered by the company’s encouraging sales performance across its business segments, especially the Pain Treatments ...

The stock price of Bioventus (BVS) has more than doubled in the past six months. This upside can be attributed to the encouraging sales performance across its business segments, based on which management raised the 2024 guidance twice this year. In the past six months, BVS stock significantly outperformed the industry's 5.1% rise. The stock has also outperformed the sector and the S&P 500 during the same period. BVS shares are also trading above the 50-day and 200-day moving averages. BVS Stock Outperforms ...

Core Viewpoint - Bioventus (BVS) is a strong buy with a focus on developing drugs for quick and safe healing, particularly targeting osteoarthritis and bone healing [1] Company Overview - Bioventus, Inc. is a medical technology company specializing in proprietary orthobiologic products for musculoskeletal conditions, founded on November 23, 2011, and headquartered in Durham, NC [2] Earnings History - Bioventus has a solid earnings history, consistently beating the Zacks Consensus in the last three quarters, with an average positive earnings surprise of 102% over the last four quarters [4] Earnings Estimates Revisions - Annual earnings estimates for Bioventus are increasing, with the full year 2024 estimate rising from $0.27 to $0.40, and next year's estimate moving up from $0.43 to $0.45 over the last 30 days [5] Growth Projections - For 2024, Bioventus is expected to achieve 9.45% growth with projected sales of $560 million, increasing to $593 million in the following year for a 5.8% growth [6] Valuation Metrics - The forward PE ratio is 24x, which is considered high for the expected topline growth, while the price to book ratio is 4.1x and price to sales ratio is 1.46x, indicating potential for revenue expansion [7] - Operating margins have improved from 1% to 5.1% and up to 5.7% over the last three quarters, suggesting that growing sales and higher margins will lead to increased earnings per share [7]

Bioventus Inc. (NASDAQ:BVS) Q2 2024 Earnings Conference Call August 7, 2024 8:03 AM ET Corporate Participants Dave Crawford - VP, IR & Treasurer Robert Claypoole - President and Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good day, and welcome to the Bioventus Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. Please note ...